Skip to main content

Table 4 Univariate and Multivariate analysis of prognostic factors for PBTC subgroup

From: Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution

Factors n(%) Univariate analysis Multivariate analysis
mOS(95%CI) χ2 p B HR(95%CI) P
Age (years)
 ≤40 8 (3.9) 5.0 (0.0-25.7) 2.455 0.653 - - -
 41-50 19 (9.2) 8.2 (3.7-12.7)    - - -
 51-60 66 (31.9) 9.0 (5.4-12.6)    - - -
 61-70 78 (37.7) 8.2 (6.2-10.2)    - - -
 ≥71 36 (17.4) 8.3 (6.3-10.3)    - - -
Sex
 Male 115 (55.6) 7.0 (5.6-8.4) 1.589 0.208 - - -
 Female 92 (44.4) 9.7 (8.3-11.1)    - - -
Pain on the back and loin
 No 128 (61.8) 8.2 (6.0-10.4) 0.909 0.340 - - -
 Yes 79 (38.2) 8.7 (6.7-10.8)    - - -
Smoking history
 No 139 (67.1) 9.6 (8.0-11.2) 1.807 0.179 - - -
 Yes 68 (32.9) 7.0 (5.7-8.3)    - - -
Diabetes history
 No 119 (57.5) 9.0 (7.6-10.4) 0.864 0.353 - - -
 Yes 88 (42.5) 7.0 (5.0-9.0)    - - -
CA199(U/ml)
 <37 50 (24.2) 10.5 (6.1-14.9) 41.985 0.000   Reference  
 ≥37and<200 54 (26.1) 12.0 (9.4-14.6)    0.056 1.058 (0.647-1.729) 0.823
 ≥200and<400 24 (11.6) 10.6 (8.0-13.2)    0.175 1.191 (0.642-2.211) 0.579
 ≥400and<800 28 (13.5) 7.6 (4.0-11.2)    0.757 2.131 (1.162-3.909) 0.015
 ≥800 51 (24.6) 5.0 (4.1-5.9)    0.813 2.255 (1.305-3.897) 0.004
CEA (ng/ml)
 <5 127 (61.4) 10.6 (8.8-12.4) 17.747 0.000   Reference  
 ≥5 80 (38.6) 6.0 (5.4-6.7)    0.508 1.661 (1.152-2.397) 0.007
Albumin(g/L)
 <35 15 (7.2) 3.2 (0.0-7.8) 1.494 0.222 - - -
 ≥35 192 (92.8) 8.7 (7.1-10.3)    - - -
Total bilirubin (umol/l)
 <22 184 (88.9) 8.8 (7.3-10.3) 9.531 0.023   Reference  
 ≥22and<100 21 (10.1) 5.4 (5.0-5.8)    0.620 1.858 (1.070-3.229) 0.028
 ≥100and<200 1 (0.5) -    -1.082 0.339 (0.038-3.042) 0.334
 ≥200 1 (0.5) -    1.780 5.927 (0.752-46.746) 0.091
Peripancreatic invasion
 No 46 (22.2) 13.4 (6.5-20.3) 10.891 0.000   Reference  
 Yes 161 (77.8) 7.5 (6.1-8.9)    0.501 1.650 (1.077-2.529) 0.021
Degree of weight loss (kg)
 <5 123 (59.4) 9.0 (7.5-10.5) 0.567 0.452 - - -
 ≥5 84 (40.6) 7.0 (5.5-8.5)    - - -
NLRa
 <2 36 (17.4) 9.0 (5.8-12.2) 0.028 0.868 - - -
 ≥2 171 (82.6) 8.3 (6.7-9.9)    - - -
NLRb
 <3 99 (47.8) 9.0 (6.7-11.3) 0.000 0.993 - - -
 ≥3 108 (52.2) 8.2 (6.6-9.8)    - - -
NLRc
 <4 124 (59.9) 9.0 (7.3-10.7) 0.190 0.663 - - -
 ≥4 83 (40.1) 7.5 (5.8-9.2)    - - -
NLRd
 <5 180 (87.0) 9.0 (7.5-10.5) 5.990 0.014   Reference  
 ≥5 27 (13.0) 3.4 (0.0-8.1)    0.500 1.649 (1.009-2.696) 0.046
Operative procedure
 Without operation 79 (38.2) 5.8 (4.9-6.7) 21.185 0.000   Reference  
 Palliative operation 10 (4.8) 2.0 (0.7-3.3)    0.615 1.850 (0.817-4.189) 0.140
 Radical resection 118 (57.0) 11.0 (8.4-13.6)    0.153 1.166 (0.785-1.731) 0.447
Tumor size (cm)
 d<2 4 (1.9) 6.0 (0.0-14.1) 2.697 0.260 - - -
 2≤d<4 74 (35.7) 9.0 (6.1-11.9)    - - -
 d≥4 129 (62.3) 8.1 (6.6-9.6)    - - -
Hepatic metastasis
 No 41 (19.8) 10.0 (8.7-11.3) 30.997 0.000   Reference  
 Yes 166 (80.2) 4.5 (2.4-6.6)    0.462 1.588 (0.966-2.610) 0.068
Lymph node metastasis
 No 141 (68.1) 7.1 (4.0-20.2) 0.091 0.763 - - -
 Yes 66 (31.9) 8.7 (7.2-10.2)    - - -
Number of distant organ metastasis
 0 119 (57.5) 11.0 (9.3-12.7) 36.997 0.000   Reference  
 1 51 (24.6) 6.0 (4.5-7.5)    0.468 1.597 (1.009-2.527) 0.046
 ≥2 37 (17.9) 4.0 (2.4-5.6)    0.771 2.163 (1.268-3.690) 0.005
Adjuvant chemotherapy
 No 188 (90.8) 7.7 (6.2-9.2) 5.857 0.016   Reference  
 Yes 19 (9.2) 17.5 (7.7-27.3)    -1.077 0.340 (0.182-0.638) 0.001
  1. NLR Neutrophil-lymphocyte ratio, HR Hazard ratio, CI Confidence interval, mOS Median overall survival
  2. p: Log Rank Mantel–Cox test; P: Cox proportional hazards model